Waypoint Bio Raises $20M Series A Led by Amplify Partners to Advance AI-Designed Cell Therapies Toward the Clinic

Waypoint Bio Raises $20M Series A Led by Amplify Partners to Advance AI-Designed Cell Therapies Toward the Clinic

Waypoint Bio, an AI-native biotech company using spatial biology to design next-generation CAR T therapies for solid tumors, announced today that it closed a $20M Series A financing round.

The financing was led by Amplify Partners and Elliot Hershberg will join the board of directors. General Catalyst, Time BioVentures, Mitsui Global Investments, and Lux Capital participated in the round, alongside existing investors including Hummingbird Ventures.

The Series A will fund advancement of Waypoint’s WAY-103 program into an investigator-initiated trial beginning in late 2026. Additionally, Waypoint will expand its AI and spatial biology platform and the buildout of its clinical development capabilities. Dr. Patrick Kaifosh, previously co-founder and Chief Scientific Officer of the neuro-AI startup CTRL-Labs and Senior Director at Meta’s Reality Labs, has joined as CTO, strengthening Waypoint’s leadership in AI and automation. Dr. Kristen Hege, formerly Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol-Myers Squibb, has joined the Scientific Advisory Board.